CYTOPROTIDIAN LIFESCIENCE CONSULTING LLC
From molecular signal to clinical decision
We pair data science and computational biology expertise with senior medical-affairs strategy, helping biotech labs and early biotechs turn complex data into confident clinical decisions. We connect multiomics and biomarker data with clinical and medical insight, so teams can find the right patients, indications and biomarkers and evidence that move a program forward.
SERVICES
Advisory Engineered for Translational Execution and Asset Progression
Each consultative initiative is structured around the core mechanistical and clinical decision matrices that determine asset viability: target validation, patient stratification, indication prioritization, and data-driven gating milestones. We assist research teams in synthesizing highly rigorous, objective evidence frameworks that withstand intense peer evaluation and align with institutional governance standards. Beyond strategic formulation, we actively collaborate at every critical juncture of the translational continuum, optimizing the operational path from preclinical proof-of-concept to clinical execution.
1
Computational Biology, Bioinformatics, AI and Data Science
Multi-omics, biomarkers, pipelines and AI-enabled analysis, from discovery to clinic.
2
Medical Affairs and Medical Strategy
Medical strategy, scientific diligence and launch readiness across the product lifecycle.
3
Translational and Clinical Development
Program strategy and cross-functional leadership, from protein to clinic.
4
Evidence, HEOR and Value
Evidence generation, gap analysis and value narratives decision-makers can trust.
5
Scientific Communications, Medical Training and Publications
Publication planning, scientific narratives and congress communications that make evidence land.
OUR EDGE
Computational rigor. Clinical judgment. One conversation.
Most computational analyses fail not because the math is wrong, but because no one with clinical experience checked whether the answer makes sense for a real patient. At Cytoprotidian, a computational biologist and a practicing physician work the same problem together, so what reaches you is already tested against both the data and the clinic.
- One conversation, not a handoff chain. The analyst and the clinician are in the same room, so there is no translation loss between them.
- Stress-tested before you commit. Every model is challenged on clinical plausibility before it informs a go/no-go decision.
- Built for the questions investors and partners ask. Your asset strategy is grounded in mechanism and patient reality, not only market logic.
Computational Biology
pipelines, models, omics, biomarkers
+
Medical Affairs
clinical strategy, evidence, patient level insights
=
Translational decisions that hold up
Asset decisions you can defend to investors, partners, and regulators
TRACK RECORD
Proof, not promises.
Cytoprotidian is new. The people behind it are not. Before founding the firm, our founders did this work inside some of the world’s largest pharmaceutical companies.
$600K
20+ centers of excellence
Teaching a machine to spot a disease most doctors never see
Fabry disease hides for years behind ordinary symptoms. Subir led an MIT-Takeda collaboration building an AI-based diagnostic approach for it, winning $600K in program funding and aligning the protocol, data framework and regulatory path across more than 20 centers of excellence.
Preclinical to post-marketing
Biomarkers that decide who belongs in the trial
The right patient-selection strategy can save a program; the wrong one can sink it. Somdutta has built patient-selection and pharmacodynamic biomarker strategies across oncology and immuno-oncology, served as global biomarker analysis lead for commercial assets, and delivered biomarker packages into regulatory submissions.
100+
patients reached
Access where none existed
Rare-disease medicines do not help patients who cannot get them. In India, Subir launched three rare-disease therapies and established the country’s first rare-disease patient access program, reaching more than 100 patients – work recognized as the best project in Takeda’s ICMEA region.
7
global product launches
Seven launches, one standard
Between them, the founders have worked the full arc from preclinical discovery to post-marketing: global launch programs for seven products across rare diseases, immunology, hematology and gastroenterology on one side; oncology programs from preclinical discovery through clinical phases to post-marketing on the other.
HOW WE WORK
Four steps from “we’re not sure” to “here’s the call.”
High-fidelity translational strategy informed by biological models and validated by clinical evidence.
1
Discover
We map your scientific question, data landscape, and decision timeline – and agree on what a good answer looks like.
2
Model
We build and interrogate computational models of your biology, testing hypotheses against your data.
3
Validate
We stress-test findings against clinical and regulatory reality, so nothing survives on math alone.
4
Translate
You get a clear, decision-ready readout and a practical path forward for your program.
WORKING WITH US
Senior people. Straight lines.
Advisory Sprint
One defined question, a fixed scope, and a decision-ready readout. The fastest way to test the fit.
Embedded Partner
Ongoing senior support inside your team’s rhythm: regular working sessions, rapid reviews, and decisions made as they arise.
Defined Project
A scoped deliverable with clear milestones – a biomarker strategy, an evidence plan, a launch readiness program, a publication plan.
Confidential by default.
We work under NDA. Your unpublished data remains yours alone, and nothing from one client’s program is ever reused for another’s. What you share through the contact form is used only to respond to you.
MEET THE FOUNDERS
Operators, not observers.
Cytoprotidian was founded by two people who have spent their careers on opposite sides of the translational gap – and decided to close it.
Co-founder – Medical Affairs and Translational Strategy
Subir Roy, MD, MBA
Subir Roy, MD, MBA, is a physician and medical affairs leader with nearly two decades of experience across global pharmaceutical and biotechnology companies, including Takeda, Novartis and Bristol Myers Squibb. He has led medical strategy, scientific diligence and launch readiness in rare diseases, immunology, hematology, gastroenterology and oncology, including global launch programs for seven products and India’s first rare-disease patient access program.
At Cytoprotidian, Subir helps biotech teams pressure-test the clinical and medical logic behind their science. Is the biological rationale strong enough? Will the evidence convince clinicians, regulators and partners? What has to be true for a promising program to become a medicine patients can actually access? His recent work includes launching Takeda’s rare disease portfolio in India,
leading an MIT-Takeda collaboration on AI-based diagnosis in Fabry disease and building global medical excellence platforms for autoimmune diseases. He holds an MD (MBBS), an MBA in Marketing and Healthcare from the Indian School of Business, and a Specialist Certification in Artificial Intelligence from Duke University.
Co-founder – Computational Biology, Bioinformatics and AI/ML
Somdutta Saha, PhD
Somdutta Saha co-founded Cytoprotidian to bring big-pharma discovery and translational science to the teams that need it most, turning complex biological data into decisions that move programs forward. She has led discovery biology and translational bioinformatics teams, and driven biomarker strategy at various biotechs and pharma. Her work has covered oncology and immuno-oncology programs from preclinical discovery through different phases of clinical trials and post-marketing studies. She has built patient-selection and pharmacodynamic biomarker strategies, and she delivered packages for regulatory submissions. She has served as the global biomarker analysis lead for commercial assets, and has provided data-driven insights for critical milestones in moving forward programs.
At Cytoprotidian, she sets the scientific standard for every engagement. She leads the firm’s work in computational biology, bioinformatics and AI/ML early discovery through clinical development. Her teams combine multiomics, clinical and real-world data using reproducible pipelines and AI-enabled workflows. She also advises early-stage AI-driven biotech companies on product strategy and clinical validation.
Somdutta holds a PhD in Bioinformatics from the University of Arkansas at Little Rock. Her doctoral research used computational modeling of antibody-antigen interactions to guide the design of targeted therapies.
ADVISORS
Depth beyond the founders.
Specialists who extend the firm’s reach where precision matters most.
Advisor – Scientific Communications and Publications
Manish Garg, PhD
Manish Garg, PhD, is a scientific communications professional with more than 15 years of experience across healthcare, pharmaceutical research and clinical practice, including global Medical Affairs and scientific publication leadership. Having worked across different roles throughout the product lifecycle, he brings a broad perspective on translating scientific evidence into impactful communications that support evolving medical and business objectives.
Drawing on experience at Takeda and Bristol Myers Squibb, he has led and contributed to global publication strategies across oncology and rare hematology, delivering 40+ scientific publication deliverables, including manuscripts published in the Journal of Clinical Oncology (JCO), JAMA Oncology, the Journal of Thoracic Oncology (JTO) and Blood, and presentations at leading congresses such as ASCO, ASH, WCLC and ISTH.
His expertise spans publication planning and execution, scientific narratives, congress communications, and dissemination of clinical, real-world and HEOR evidence. He combines scientific depth with a strategic, hands-on approach, partnering with cross-functional teams, key opinion leaders and external agencies to deliver high-quality communications throughout the product lifecycle. His focus is helping pharmaceutical and biotech organizations maximize the value of scientific evidence through strategic, credible and high-impact scientific communications.
CONTACT
Tell us your challenge.
Describe the problem you’re facing and how you’d like it solved. We’ll build exactly what you asked for – and then we’ll push back with alternate options you haven’t considered. The best solutions survive a good challenge.
We reply within 24 hours. Your details stay with us.